PixarBio has announced that it will stay focused on its NeuroRelease Pain platform and continue to drive non-opiate non-addictive morphine replacement to market with FDA approval expected between the end of 2018 and early 2019.

PixarBio has an IP portfolio covering pain, spinal cord injury and epilepsy, and the company believes that it will become a future market leaders with its existing and growing PixarBio patent and IP portfolio for various drug delivery systems.

On behalf of the shareholders and board of directors of PixarBio, the company withdraws its offer for InVivo Therapeutics for reasons related to management credibility and competence, corporate governance and IP control.

PixarBio is a public company traded on the OTC markets under the stock symbol PXRB. PixarBio is a specialty pharmaceutical/biotechnology company focused on pre-clinical and clinical commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, devices, or biologics to treat pain, epilepsy, Parkinson’s disease and spinal cord injury. Our lead product platform, NeuroRelease, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in preclinical models.